Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)

NCT06419621 is registered in ClinicalTrials.gov with Biotheus Inc. as lead sponsor.

NCT NCT06419621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06419621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)
Lead sponsor
Biotheus Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 11, 2024
Completion date
July 31, 2028
Enrollment
392 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer(tnbc)